http://www.acc.org/Feed?clinicalTopicID=9d928ff7-0a69-4d5c-8ae4-9a5be446fc6b Clinical Topic Feed: Atrial Fibrillation/Supraventricular Arrhythmias en /Latest-in-Cardiology/Articles/2026/03/31/12/36/accel-lite-31mar2026 Caffeinated coffee may reduce the risk of atrial fibrillation through several proposed mechanisms, including improved autonomic balance, antioxidant effects, and enhanced vascular function. 1774960800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-trifr-acc-2026 Transcatheter tricuspid edge-to-edge repair (T-TEER) in addition to standard-of-care medical therapy reduced the risk of death, myocardial infarction (MI), stroke and hospitalization for heart failure (HF) compared with standard-of-care alone in patients with severe symptomatic tricuspid regurgitation (TR)... 1774818180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-surviv-acc-2026 Among patients with a failed mitral bioprosthetic valve, transcatheter mitral valve-in-valve (mVIV) treatment was associated with a lower rate of death or disabling stroke at one year compared with standard repeat mitral valve replacement surgery (rMVR), according to results from the SURVIV study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans. 1774818000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/28/21/40/The-Future-of-AI-and-CV-Medicine-Early-Detection-Data-Driven-Action Artificial intelligence (AI) is increasingly touching more aspects of modern life, offering great promise, but also great risk. The great potential and concerning influences of AI on medicine, clinicians and patients will be examined by one of its early adopters, Paul A. Friedman, MD, during today’s Eugene Braunwald Keynote. 1774782000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-championaf-acc-2026 Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, or systemic embolism at three years in patients with atrial fibrillation (AFib) who were candidates for anticoagulation, based on findings from the CHAMPION-AF trial presented at ACC.26 and simultaneously published in NEJM. In addition, LAA closure was superior to long-term NOAC therapy for pre-specified non–procedure-related bleeding over the same time period. 1774708380000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/24/18/20/New-ECSOCDD-TTVI A new multisociety Expert Consensus Systems of Care document provides operator and institutional recommendations and requirements for tricuspid interventions. Published in JACC, the document provides guidance on implementing and maintaining a transcatheter tricuspid valve intervention (TTVI) program in a rapidly evolving field. 1774451280000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/24/17/35/What-is-the-Frequency In patients with congenital heart disease who undergo transcatheter pulmonary valve replacement (TPVR) with either balloon-expandable or self-expanding pulmonary valve replacement (BEPVR and SEPVR), a retrospective study and a registry study show that arrhythmias are common in the early period, with differences over time and by device. Both studies were published March 23 in JACC: Clinical Electrophysiology. 1774376160000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/24/17/43/CLOSURE-AF Catheter-based closure of the left atrial appendage (LAA) was found to be not noninferior to physician-directed best medical care for the primary composite endpoint of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death among patients with atrial fibrillation (AFib) and a high risk of stroke or bleeding, according to results of the CLOSURE-AF trial published March 18 in NEJM. 1774376160000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/18/16/54/ACC26-Science-Published-Across-JACC-Journals-acc-2026 The following science will be presented during ACC.26 in New Orleans and was simultaneously published in JACC, JACC: Cardiovascular Interventions, JACC: CardioOncology, JACC: Clinical Electrophysiology and JACC: Heart Failure. 1773855600000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/12/18/40/JACC-State-of-the-Art With the population of stage D heart failure (HF) patients supported with durable left ventricular assist devices (dLVAD) rapidly expanding, a State-of-the-Art Review published in JACC provides a comprehensive overview of support and management of dLVAD-related emergencies, with an intent to provide a rapid-response guide for clinicians who encounter emergencies in patients with dLVADs. 1773343260000 Articles and Stories